Cumberland Pharmaceuticals Inc: Form 10-Q for the period ended Jun 30, 2019
Filed with the SEC on Aug 14, 2019 and accepted by EDGAR at Aug 14, 2019, 17:28 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2019-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2019-04-01 to 2019-06-30 | $11.6m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 6 months2019-01-01 to 2019-06-30 | $23.5m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2019-04-01 to 2019-06-30 | $2.0m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 6 months2019-01-01 to 2019-06-30 | $4.0m | us-gaap:CostOfGoodsAndServicesSold |
| Research and development | 3 months2019-04-01 to 2019-06-30 | $1.5m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2019-01-01 to 2019-06-30 | $2.7m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2019-04-01 to 2019-06-30 | −$601.7k | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2019-01-01 to 2019-06-30 | −$778.5k | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2019-04-01 to 2019-06-30 | $91.2k | us-gaap:InterestExpense |
| Interest expense | 6 months2019-01-01 to 2019-06-30 | $152.1k | us-gaap:InterestExpense |
| Income tax | 3 months2019-04-01 to 2019-06-30 | $4.5k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2019-01-01 to 2019-06-30 | −$77.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2019-04-01 to 2019-06-30 | −$549.5k | us-gaap:NetIncomeLoss |
| Net income | 6 months2019-01-01 to 2019-06-30 | −$623.4k | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2019-04-01 to 2019-06-30 | −$0.04 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2019-01-01 to 2019-06-30 | −$0.04 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2019-04-01 to 2019-06-30 | −$0.04 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2019-01-01 to 2019-06-30 | −$0.04 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2019-04-01 to 2019-06-30 | 15,523,628 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2019-01-01 to 2019-06-30 | 15,497,989 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2019-01-01 to 2019-06-30 | $1.5m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2019-01-01 to 2019-06-30 | $89.1k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 6 months2019-01-01 to 2019-06-30 | $1.2m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2019-06-30 | $21.0m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2019-06-30 | $51.9m | us-gaap:AssetsCurrent |
| Total assets | At period end2019-06-30 | $107.5m | us-gaap:Assets |
| Current liabilities | At period end2019-06-30 | $22.3m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2019-06-30 | $53.9m | us-gaap:Liabilities |
| Shareholders' equity | At period end2019-06-30 | $54.1m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001628280-19-010781. Last ingested by Listed: Nov 11, 2026, 03:05 ET. Listed shows no prices and gives no investment advice.